Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

hase 2 clinical trial in patients with non-Hodgkin's lymphoma with blinatumomab. In addition, by mid-2009, we expect to have completed enrollment in the ongoing phase 2 clinical trial in patients with acute lymphoblastic leukemia.
  • By mid 2009, we expect our partner Nycomed to initiate the first phase 1 clinical trial with MT203, a GM-CSF-neutralizing human monoclonal antibody, for the treatment of chronic inflammatory and autoimmune diseases.
  • Later in 2009, we expect our partner Morphotek, a wholly-owned subsidiary of Eisai, to initiate a first phase 1 clinical trial with MT228, a glycolipid-binding human antibody.
  • Also later in 2009, we expect our partner TRACON Pharmaceuticals, Inc. to complete the ongoing phase 1 clinical trial of MT293, a humanized monoclonal antibody targeting denatured collagen, that is being developed for the treatment of solid tumors.
  • Micromet intends to publish results from the research and development of its programs in peer-reviewed scientific and clinical journals throughout the year.
  • As previously stated, Micromet entered into an agreement with Bayer Schering in January 2009 under which Bayer Schering has obtained an exclusive option to develop and commercialize a BiTE antibody against a specified solid tumor target. We intend to enter into at least one additional corporate collaboration in 2009.
  • Financial Results:

    Quarter Ended December 31, 2008

    For the three months ended December 31, 2008, Micromet recognized total revenues of $5.9 million, compared to $7.0 million for the same period in 2007. Total operating expenses were $12.4 million for the three months ended December 31, 2008, compared to $13.1 million for the same period in 2007.

    Loss from operations for the three months ended December 31, 2008 was $6.5 million, compared to a loss from operations of
    '/>"/>

    SOURCE Micromet, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
    2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
    3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
    4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
    5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
    6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
    7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
    8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
    9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
    10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
    11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/22/2014)... The identification of protein-coding variants ... accelerated by exome sequencing. Built on Roche NimbleGen’s ... SeqCap EZ Developer system has been a proven ... additionally present how he achieved coverage statistics similar ... mouse exome kits. With over 236,000 SNPs and ...
    (Date:8/21/2014)... Aug. 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... first in class collagenase-based products marketed as XIAFLEX ... the U.S. and XIAPEX ® in the ... a randomized, double-blind Phase 2a study of CCH ... fibrosclerotic panniculopathy. The results showed that all three ...
    (Date:8/21/2014)... A Finnish-Swedish research group at the Institute for ... Karolinska institutet, Stockholm, has developed a novel "man ... infection. This innovative diagnostic aid was described in ... August. The method is based on computer vision ... systems combined with visualization of only the diagnostically ...
    (Date:8/21/2014)... August 21, 2014 2014 ... Industry” is a professional and in-depth research ... report provides basic Seaweed Fertilizer information, including ... chain structure as well as industry overview. ... including domestic market as well as global ...
    Breaking Biology Technology:Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3
    ... Calif., March 9 Cord Blood America, Inc. (OTC ... preservation company ( http://www.cordblood-america.com ) focused on bringing ... nationwide and internationally, said today that it believes the ... on Federal funding of stem cell research is a ...
    ... YORK, March 9 Cynvec LLC, a privately held ... harness the apoptotic ability of the sindbis viral vector, ... Officer, will present at the Cowen and Company 29th ... 16, 2009 at 4:00 p.m. ET. About ...
    ... CAMBRIDGE, Mass., March 9 Merrimack Pharmaceuticals, Inc., a ... development of novel treatments for cancer and autoimmune disease, ... to Senior Vice President and Chief Scientific Officer and ... Business Development. "Ulrik and Tad have both played ...
    Cached Biology Technology:Cord Blood America Sees Significant Positives in President Obama's Lifting of Stem Cell Funding Restrictions 2Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development 2
    (Date:8/21/2014)... feeding tube connectors, designed by an international standards process, ... , According to an invited review published in the ... ( NCP ), the official journal of the American ... connectors will greatly reduce the occurrence of misconnection that ... Small-bore connectors, which are used to join medical devices, ...
    (Date:8/21/2014)... successfully replicated one of the crucial steps in photosynthesis, ... which could manufacture hydrogen as a fuel. , "Water ... exciting prospect to use them to create hydrogen, and ... from the ARC Centre of Excellence for Translational Photosynthesis ... offers potential as a zero-carbon replacement for petroleum products, ...
    (Date:8/21/2014)... in severe abdominal pain, vomiting and systemic inflammation. Every ... with the disease resulting in 1000 deaths. There is ... fluid and nutritional support. , Dr Jason Bruce, ... research, said "The major causes of pancreatitis include bile ... combined with a high fat diet. In fact, the ...
    Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Water and sunlight the formula for sustainable fuel 2Insulin offers new hope for the treatment of acute pancreatitis 2
    ... NY, October 13, 2010Parents of children with undiagnosed learning ... of psychological and social challenges, which are explored in ... and Molecular Biomarkers , a peer-reviewed journal published by ... is available free online ahead of print at ...
    ... solved an important mystery about why an arsenic compound, ... an effective therapeutic agent against disease and infections. According ... of Genetics ( http://www.genetics.org ) scientists from ... common water contaminant in many parts of the world, ...
    ... new study conducted by a researcher at Ben-Gurion University ... Social Policy Studies in Israel reports that Israeli,s have ... residents of other OECD (Organization for Economic Cooperation and ... from 2005, the average American life expectancy is now ...
    Cached Biology News:Unexplained childhood disorders 2Scientists solve mystery of arsenic compound 2Life expectancy higher in Israel than in US, according to Ben-Gurion U. researcher 2
    Quantibody Human Angiogenesis Array 1 (1 slide) Class: Quantitative Antibody Arrays Product Group: Antibody Array...
    Vertical Rack (five box vapor phase rack), includes 2.0" (5.1cm) boxes...
    ... PAGE Cleavable ICAT Reagent ... Protein ID and Quantitation ... Electrophoresis (PAGE), isotope-coded affinity ... technology to facilitate the ...
    Conjugate Quality Control Evaluation Specificity: Conjugate Quality Control Evaluation ...
    Biology Products: